Vecchiarelli P, Ricci F, Tessero D, Quadrani G, Natalini L
Servizio di Anestesia e Rianimazione, USL VT/3-Viterbo, Ospedale di Belcolle.
Minerva Anestesiol. 1995 Oct;61(10):415-20.
Phenformin, a drug used in the treatment of diabetes mellitus frequently associated with potentially fatal cases of lactic acidosis, has been removed from market in the USA and several European countries. However, cases of lactic acidosis are still reported in countries where phenformin is available, either because well-known contraindications for its use are not observed, or because the prodromic syndrome of the lactic acidosis is not diagnosed. This study describes two cases of lactic acidosis, the treatment used and the final outcome. The authors point out that plainly evident contraindications were ignored in both cases, while the prodromic syndrome remained unrecognized even by specialists. The management of lactic acidosis continues to be a challenge. There is no optimal treatment and early recognition is essential. The authors call for greater attention in the use of phenformin and its eventual removal from market, especially in the light of alternative therapies which prove to be equally valid and easier to administer.
苯乙双胍是一种用于治疗糖尿病的药物,常与潜在致命的乳酸性酸中毒病例相关,已在美国和几个欧洲国家退市。然而,在仍有苯乙双胍供应的国家,仍有乳酸性酸中毒病例报告,要么是因为未遵守其已知的使用禁忌,要么是因为乳酸性酸中毒的前驱综合征未被诊断出来。本研究描述了两例乳酸性酸中毒病例、所采用的治疗方法及最终结果。作者指出,在这两例病例中,明显的禁忌都被忽视了,而前驱综合征甚至连专家都未识别出来。乳酸性酸中毒的管理仍然是一项挑战。目前尚无最佳治疗方法,早期识别至关重要。作者呼吁在使用苯乙双胍时要给予更多关注,并最终将其从市场上撤下,尤其是鉴于替代疗法同样有效且更易于给药。